PHƯƠNG PHÁP ĐIỀU TRỊ VÀ ĐẶC ĐIỂM MÔ BỆNH HỌC CỦA BỆNH NHÂN U MÁU GAN

Abstract

Background: Hemangioma is the most common benign tumor in the liver, if the tumor is large, appropriate treatment must be indicated. Objectives: To evaluate treatment indications and histopathological results of hepatic hemangioma patients. Methods: A cross-sectional study of 49 patients diagnosed with hepatic hemangioma based on the guidelines of the EASL. On contrast-enhanced CT image, hemangioma showed enhancement peripheral in arterial phase, afferent enhancement in delayed phase; diagnosed by histopathology when the tumor is not typical enhancement on CT. Results: RFA was the most performed treatment with the rate of 34.7%. Resection and TAE together with the rate of 14.3%. Tumor resection was performed at the youngest age of 42.4 ± 10.9, the RFA group was 48.2 ± 11.4; TAE group is 64.8 ± 23.3; p = 0.01. The average tumor size of the tumor resection group was the highest 7.1 ± 2.7 cm, the RFA group had the lowest size 5.8 ± 2.6 cm, the tumor size of the TAE group was 6.6 ± 1.8 cm, p = 0.01. The mean tumor size of the needle biopsy group was 3.3 ± 0.9 cm, smaller than that of the cold biopsy group, 7.1 ± 2.7 cm, p = 0.009. In 13 patients undergoing biopsies, the benign rate was 100%. Cavernous hemangiomas account for 69.2%, capillary hemangiomas account for 30.8%. Conclusion: It is possible to perform resection, RFA, TAE for hepatic hemangioma patients depending on the case. Hemangioma of large size is still benign in nature.